CABA Projected Dividend Yield
Cabaletta Bio Inc ( NASDAQ : CABA )Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Co.'s proprietary technology utilizes Chimeric AutoAntibody Receptor, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Co.'s main CAAR T cell product candidate was designed based on the Chimeric Antigen Receptor, T cell technology that is marketed for the treatment of B cell cancers. Co.'s initial focus is mucosal pemphigus vulgaris, which is an autoimmune blistering disease. 20 YEAR PERFORMANCE RESULTS |
CABA Dividend History Detail CABA Dividend News CABA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |